Who We Are
A different kind of biotechnology organization.
Built to make rare disease therapies possible.
Aurelix Bio brings together scientific innovation, integrated therapeutic development, and sustained program leadership to build and advance genetic medicines for rare and ultra-rare diseases.
We combine scientific and clinical expertise with innovative development strategies to create more efficient, cost-effective pathways from promising science toward patients.
Why Aurelix Exists
The science exists. The need is real.
Rare and ultra-rare diseases affect some of the most vulnerable patients—often children—who have no approved treatments and no clear path forward.
The scientific tools to address many of these diseases now exist. What has been missing is the sustained development infrastructure to carry promising science from discovery toward patients.
Aurelix was built to close that gap—providing the scientific leadership, regulatory expertise, clinical development capabilities, and organizational commitment that rare-disease programs need to move forward.
We exist because these patients deserve the same quality of development, the same rigor, and the same determination that larger programs receive.
Our Founder
Dr. Brandon M. Henry, MD
Founder, Chief Executive & Medical Officer
Physician-scientist. Rare disease advocate. Builder.
Building the infrastructure rare-disease programs need to succeed.
Dr. Brandon M. Henry is a physician-scientist and therapeutic development leader working at the intersection of scientific discovery, genetic medicine, and clinical development. His work focuses on advancing therapies for rare and ultra-rare diseases, bringing together scientific innovation, regulatory strategy, clinical development, and the sustained leadership required to move promising medicines toward patients.
His experience spans AAV and lentiviral gene therapy, genome editing, RNA therapeutics, and individualized therapeutic development. He has provided scientific, medical, and development leadership across programs ranging from early translational research through IND clearance and first-in-human clinical investigation.
Previously, Dr. Henry served as Medical Director of the Cell & Gene Therapy Center of Excellence at IQVIA. He also serves as Chief Medical Officer of the FOXG1 Research Foundation, Chief Scientific Officer of the CACNA1A Foundation, and Chief Drug Development Officer of the Raiden Science Foundation, supporting independently sponsored therapeutic development programs for rare neurological and genetic diseases.
An internationally recognized researcher, Dr. Henry has authored more than 400 peer-reviewed scientific publications and has been recognized as a Clarivate Highly Cited Researcher and among the Stanford/Elsevier Top 2% Scientists.
He founded Aurelix Bio to build an integrated therapeutic development organization capable of bringing together scientific expertise, development innovation, strategic partnerships, and sustained program stewardship to create more efficient and cost-effective pathways for genetic medicines.
Why I Built Aurelix
I have spent my career at the intersection of science and medicine, working to turn promising discoveries into therapies that can reach patients. But working alongside families affected by rare diseases has made the stakes of drug development deeply personal.
I have seen what it takes to move a therapy from an idea toward the clinic—the scientific challenges, the difficult decisions, and the people who come together to make that progress possible. I have also seen how much work remains after the first patient is treated.
I built Aurelix to take on that larger challenge: bringing together scientific innovation, integrated development, and sustained program leadership to build therapeutic programs that can keep moving forward—and ultimately make disease-modifying therapies accessible to every patient who could benefit.
For children and families waiting for treatment, failure is not an option.
Our Leadership
The experience to build. The commitment to see it through.
Aurelix brings together expertise in scientific discovery, therapeutic development, and patient advocacy. Our leadership combines the experience needed to build genetic medicines with a shared commitment to the people waiting for them.
Amber Freed
Chief Growth Officer
Reimagining how therapies are funded, advanced, and delivered to patients
Amber leads business strategy, partnerships, and innovative funding models at Aurelix Bio. She focuses on building integrated ecosystems that accelerate development and unlock new pathways for rare disease therapies.
She brings a unique combination of strategic and lived experience, having driven her own son's gene therapy from bench to clinic. Since his diagnosis with SLC6A1, she has advanced multiple translational programs and emerged as a leader in patient-led drug development.
Amber is the Founder and CEO of SLC6A1 Connect, where she has mobilized global research, funding, and advocacy to advance treatment development.
Subha Karumuthil-Melethil, PhD
Head of Discovery and Translational Research
Designing translational strategies that move AAV gene-therapy targets from discovery to clinic.
Dr. Karumuthil-Melethil leads Discovery and Translational Research, ensuring early scientific innovation is translated into rigorous, target-driven programs that advance toward clinical development.
She brings deep expertise in AAV gene therapy and translational target identification, with a track record of developing novel approaches to overcome challenges in vector biology and target selection. Previously Director of Gene Therapy Research and Target Discovery at REGENXBIO, Subha was honored with the President's Award for her innovation and persistence.
At Aurelix, Subha aligns discovery strategy with clinical and regulatory objectives, establishing clear go/no-go criteria, defining critical assays and controls, and positioning programs for successful IND submission and clinical execution.
Why We Keep Building
For the patients waiting today. And every patient who could benefit.
We built Aurelix to carry promising science further—with the scientific rigor, sustained development, and determination needed to create treatment opportunities for more patients.